Decernotinib
- VX-509 - VRT-831509 - Adelatinib
- Optical Purity: 0.99
- Soluble in DMSO
- MF: C18H19F3N6O
- MW: 392.38
Description
Decernotinib is an orally bioavailable Janus kinase 3 (JAK3) inhibitor, potently and selectively inhibiting the enzyme with an in vitro Ki of 2.5 nM, and IC50 of 50-170 nM in cellular assays dependent on JAK3 activity. Highly selective, displaying no activity (with limited or no measureable potency) towards other JAK and non-JAK enzymes. Showed in vivo activity in two animal models of aberrant immune function, and demonstrated dose-dependent reduction in ankle swelling and paw weight and improved paw histopathology scores in the rat collagen-induced arthritis model.
More Information
| Parent CAS No. | 944842-54-0 |
|---|---|
| Chemical Name | (R)-2-(2-(1H-Pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-ylamino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide |
| extra_info | Sold in collaboration with Chemietek |
| SMILES | C1(C2C3C=CC=NC=3NC=2)N=C(N[C@](C)(CC)C(=O)NCC(F)(F)F)C=CN=1 |&1:13,r| |
| MFCD | N.A. |
| InChi | InChI=1S/C18H19F3N6O/c1-3-17(2,16(28)25-10-18(19,20)21)27-13-6-8-23-15(26-13)12-9-24-14-11(12)5-4-7-22-14/h4-9H,3,10H2,1-2H3,(H,22,24)(H,25,28)(H,23,26,27)/t17-/m1/s1 |
| InChiKey | ASUGUQWIHMTFJL-QGZVFWFLSA-N |
| CID | 59422203 |
| Short Description | JAK3 inhibitor |
Related Products
| AXON ID | NAME | FROM PRICE |
|---|---|---|
| 1338 | CP 690550 |
From $66.00 |
| 2072 | Tofacitinib citrate |
From $126.50 |
| 2217 | PF 956980 |
From $99.00 |
| 3950 | Peficitinib |
From $132.00 |
| 3997 | ASN-002 |
From Inquiry |
| 4006 | GLPG-0634 |
From Inquiry |
| 4124 | Momelotinib hydrochloride |
From $132.00 |
| 4386 | JAK inhibitor I |
From $143.00 |
| 4393 | Ilunocitinib |
From $231.00 |
